Keynote Speakers

We are very proud to announce our confirmed Keynote Speakers:


Professor Olli Kallioniemi

Olli Kallioniemi is Professor in Molecular Precision Medicine at the Karolinska Institutet and Director of the Science for Life Laboratory (, a national infrastructure for life sciences in Sweden since 2015.

Professor Kallioniemi received his M.D. in 1984, Ph.D. in 1988 and specialty training in laboratory medicine at the University of Tampere in Finland. He undertook a postdoc at UC San Francisco in 1990-1992 and was appointed faculty at the National Human Genome Research Institute, at the NIH (1995-2002). He was the founding director of the Medical Biotechnology unit at Turku, Finland at the VTT Technical Research Centre and University of Turku (2002-2008). He was the Founding Director of FIMM – the Institute for Molecular Medicine Finland ( and professor at the University of Helsinki in 2007-2015. FIMM is part of the Nordic EMBL partnership in Molecular Medicine.

Professor Kallioniemi is an author of 367 publications, a member of the editorial board of six journals and has been an invited key note lecturer in over 150 meetings during the past five years. He has supervised 23 doctoral theses and has been an advisor to 27 postdocs. Professor Kallioniemi is an inventor and co-inventor of 24 issued patents, with a focus on diagnostic technology development, such as FISH, CGH, tissue microarrays, cell-based RNAi microarrays and bioinformatic methods. His current research is focussing on individualized systems medicine to promote precision care of cancer patients.


Dr Susan Chang

Susan Chang, MD, is the Director of the Neuro-Oncology Division at the University of California at San Francisco (UCSF), and she specializes in the treatment of adults with brain tumors.  Dr. Chang received a medical degree from the University of British Columbia and completed a residency in internal medicine at Toronto General Hospital in Canada. She completed a fellowship in medical oncology at Princess Margaret Hospital in Toronto as well as a fellowship in neuro-oncology at the UCSF, where she later joined the faculty.

Dr. Chang performs clinical trials about brain tumor therapy protocols and experimental therapeutic regimens for adult patients. In addition to research into developing novel and effective therapeutic strategies for the treatment of patients with primary brain tumors, her research goals have expanded to include the evaluation of novel imaging techniques that may influence treatment selection for patients. She is the co-PI of a program project grant evaluating imaging and tissue biomarkers of glioblastoma and has recently been co-recipient of a SPORE project for evaluating the role of magnetic resonance spectroscopy in diagnosing tumors and evaluating therapeutic interventions.  Dr. Chang has developed a caregiver program for patients with brain tumors at UCSF and is the editor in chief of a newly launched journal Neuro-Oncology Practice that focuses on the clinical aspects of the management of patients with an emphasis on quality of life and neuro-cognitive function. 


Invited Speakers

Professor Sanchia Aranda

Professor Sanchia Aranda was appointed as CEO of Cancer Council Australia in August 2015. In this role Sanchia leads cancer policy and advocacy development, ensuring a strong evidence base is used to inform cancer control in Australia. She also holds academic appointments with the University of Melbourne, University of Technology, Sydney and the University of Sydney. She has 38 years’ experience in cancer control and has held roles in healthcare, research, tertiary education and government prior to joining the not-for-profit sector. She has held significant leadership roles in Australian Cancer Control, including 8 years on the Advisory Council for Cancer Australia (2006-2015).

Sanchia also has extensive international cancer control experience, with 16 years on the board of the International Society of Nurses in Cancer Care, including 4 as President (2006-2010). She is the President for the Union for International Cancer Control and has been on the board of UICC for 6 years. She is also a board member for the International Collaboration on Cancer Reporting and the Clinical Oncological Society of Australia. Her contributions to cancer control have been recognized nationally and internationally through awards and keynote speaker invitations. In 2013 she was named the 4th Peter MacCallum Cancer Centre Distinguished Fellow for her contributions to Cancer Nursing and in 2016 received the International Society of Nurses in Cancer Care Distinguished Merit award.

Professor Michael Boyer

Professor Michael Boyer AM is a medical oncologist at Chris O’Brien Lifehouse, and holds the position of Chief Clinical Officer of that organisation. He is also a Conjoint Professor of Medical Oncology (Thoracic Oncology) at the University of Sydney and Director of the Sydney Catalyst Translational Cancer Research Centre. He trained in medical oncology at Royal Prince Alfred and Westmead Hospitals, and has a PhD in cell biology from the University of Toronto. Previously, he was on the senior staff of the Sydney Cancer Centre and Royal Prince Alfred Hospital from 1993 to 2013. Professor Boyer has 25 years of experience in the management of thoracic malignancies and head and neck cancers. His major research interest is in clinical trials of new agents in the management of lung cancer, mesothelioma and head and neck cancers.

Professor Karen Canfell, Cancer Council NSW

<photo and bio coming soon>

Professor Paul de Souza

Professor Paul de Souza trained in medical oncology at St George and Prince of Wales Hospitals, and was Research Assistant Professor at the University of Virginia (1994-1997). He is the Foundation Professor of Medical Oncology at University of Western Sydney and Liverpool Hospital, and the Director of CONCERT, a NSW Cancer Institute funded translational cancer research centre. He has sub-specialty clinical interests in genitourinary cancer, brain cancer and clinical trials. He runs a cancer research laboratory at the Ingham Institute, Liverpool Hospital, and the Phase I trials unit at Liverpool Hospital. His research interests include liquid biopsies, immune-oncology, and biomarkers.

Professor Ewa Goldys

Professor Ewa M. Goldys is Deputy Director of the Australian Research Council Centre of Excellence in Nanoscale Biophotonics ( and Professor at the Graduate School of Biomedical Engineering, the University of New South Wales, Sydney, Australia. She is Fellow of the Australian Academy of Technological Science and Engineering (ATSE), Society for Optics and Photonics (SPIE), the Optical Society and winner of the 2016 Australian Museum Eureka Prize for ‘Innovative Use of Technology’.

Her research spans the interface of ultrasensitive optical characterization, biotechnology, materials science and photonics. A portfolio of her works is centred on the development and understanding of luminescence emission in doped nanocrystals where she developed advanced methods of synthesis and characterisation of fluorescent nanoparticles for applications in fluorescence labelling. Her expertise in ultrasensitive optical characterisation and nanotechnology led to the development of novel approaches to biochemical and medical sensing and diagnostics. Current projects focus on label-free non-invasive high content cellular imaging and characterisation of cell subpopulations, on nanoparticle chemical sensors and theranostics.

Dr Elin Gray, Edith Cowan University

Dr Elin Gray is a Cancer Research Trust Postdoctoral Fellow at the School of Medical Sciences at Edith Cowan University. Dr Gray completed a BSc in Biochemistry at the University of Havana, Cuba, and obtained her PhD degree at University of Witwatersrand, Johannesburg, South Africa. She was a visiting Fogarty Fellow at the Vaccine Research Centre at the NIH, Maryland; and at Duke University, North Carolina, USA. Since, moving to Perth in 2011, her research has focused on identifying blood biomarkers for diagnosis of melanoma and to guide treatment decisions. Her team utilises and develops novel genetic analysis methodologies to interrogate biomarkers such as circulating tumour cells, circulating tumour DNA and exosomes, to provide information on the tumour evolution and cancer development. In addition, Elin is interested in identifying mechanisms of drug resistance and developing better treatment strategies. Dr Gray works in close collaboration with leading oncologists and pathologists to translate these results into clinical application.

Professor Paul Keall, The University of Sydney

Professor Paul Keall is an NHMRC Senior Principal Research Fellow and the Director of the ACRF Image X Institute at the University of Sydney. His team of scientists, clinical partners and international collaborators create, share and apply novel cancer imaging and targeted radiotherapy methods. Several of these innovations have been translated to clinical practice for improved health care. Since being awarded his Ph.D. in 1996 he has risen to be in top tier of cancer imaging and radiotherapy researchers internationally. He was the Director of the Radiation Physics Division at Stanford University (2006-2010) and then was awarded an Australia fellowship to join the University of Sydney.




Professor Rajiv Khanna, QIMR Berghofer Medical Research Institute

Prof. Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR), Brisbane Australia. He is the founding Director/Coordinator of Australian Centre for Vaccine Development (now named as QIMR Berghofer Centre for Immunotherapy and Vaccine Development). He holds Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia and is also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane, Australia. Prof. Khanna is a Fellow of Australian Academy of Health and Medical Sciences and was awarded Order of Australia in 2017. He has extensive expertise in immunotherapy clinical trials, cancer immunology and vaccine development. Over the last two decades, his group has successfully translated his research towards the development of novel T cell-based immunotherapeutic strategies for the treatment of cancer patients and transplant recipients. Prof. Khanna has been appointed as a consultant to Atara Biotherapeutics (US), CSL Ltd, Cellestis Ltd and Oxford Immunotech (UK) for the development of novel immunotherapeutics, diagnostic technologies and vaccines. He is also appointed on Scientific Advisory Board of Atara Biotherapeutics. Prof. Khanna has been invited by International Transplant Society to participate in the development of guidelines for the clinical management of cytomegalovirus infection in solid organ transplant patients.

Sir Lorimer Dods Professor Roger Reddel, Children's Medical Research Institute

<photo and bio coming soon>

A/Professor Patricia Valery, QIMR Berghofer Medical Research Institute

A/Prof Patricia Valery is a medical epidemiologist with extensive experience in public health and health service research. In her career she has made significant contributions in key areas: cancer epidemiology, translational research, and Indigenous health research. She is the principal investigator of a large program of work studying supportive care needs and patterns of care for Aboriginal and Torres Strait Islander people with cancer. Improving the coordination and continuity of care from cancer diagnosis through to management of cancer is an important step for improvement in the health of the increasing numbers of Indigenous Australians with cancer. Gaps in the research exist about what happens to Indigenous people with a cancer when they complete treatment and are discharged from hospital. A/Prof Valery is currently studying the patterns of care of Indigenous cancer patients at the Primary Health Care setting.


Professor David Whiteman, QIMR Berghofer Medical Research Institute

Professor David Whiteman is a cancer epidemiologist with a special interest in the causes, control and prevention of cancer. He received his medical degree from the University of Queensland in 1991, and his PhD in 1997. Professor Whiteman has an international reputation for research into cancers of the skin and gastrointestinal tract, and for his more recent work on cancer control.

In addition to his research activities, he is a Fellow of the Australian Academy of Health and Medical Sciences and a Fellow of the Australasian Faculty of Public Health Medicine. He currently chairs the Barrett’s Neoplasia Guidelines Committee for Cancer Council Australia and the Breast Cancer Risk Factors Working Group for Cancer Australia.


Registration Now Open

Key Dates

Conference Dates:
11 - 12 October 2018
Early Bird Registration Opens
Tuesday 3 April 2018
Early Bird Registration Close
Friday 3 August 2018
Abstracts Close
Friday 25 May 2018

Click here to save the Conference dates to your calendar!

Join our mailing list

Join our mailing list to be kept up to date with information on the Conference.

Conference Managers

Arinex Pty Ltd

Arinex Pty Ltd

ABN 28 000 386 676
Level 10, 51 Druitt Street,
Sydney, NSW 2000
Ph: +61 2 9265 0700
Fax: +61 2 9267 5443

Share Conference news, information & more

Host institutions








white space